Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Riociguat 2.5 mg vs Adempas in Healthy Male Subjects
NCT06180096Phase 1Completed
- Sponsor
- Humanis
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of riociguat in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 48 hours and AUC from time 0 to last collection time t at 48 hours. Started Mar 2023; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06180096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180096.